Ipsen plans to relocate its U.S. R&D operations to Cambridge, Mass., in 2014. This site will be key for innovation in targeted therapies across Ipsen's specialty areas as well as a center of excellence for peptides. The move also brings Ipsen closer to several key partners based in the Cambridge area, including prominent hospital centers, medical schools, biotech companies and universities, thereby further promoting and facilitating partnerships and open innovation.
Ipsen is a global specialty-driven pharmaceutical company. In 2012, R&D expenditure totaled close to $338.6 million. The company has approximately 4,900 employees worldwide.